Emergex
  • About Us
      • Team
      • Board of Directors
      • Special Advisors
  • Technology
      • Advantages of Emergex’s Vaccines
      • Set-point Vaccines
  • Pipeline
  • Media Centre
      • Press Releases
      • In the News
      • White Papers
  • Contact Us
  • Menu Menu
You are here: Home

Developing set-point vaccines against viral and bacterial infectious diseases, using purely synthetic non-biological components that prime immune cells to destroy pathogen infected cells

More

About us

Technology

Pipeline

Emergex Vaccines

We work on addressing some of the world’s most immediate health threats including viral diseases such as Dengue Fever, Zika, Ebola and pandemic Flu, as well as serious intra-cellular bacterial infections, and we have a growing pipeline of vaccine candidates.

More

Latest news

  • Emergex Vaccines signs Collaboration Agreement with Brazil’s Bio-Manguinhos/Fiocruz for the Development of a COVID-19 Vaccine 5 January 2021
  • Emergex Vaccines Raises US$11 million to Advance Pipeline of Synthetic T-Cell Vaccines for Infectious Diseases 18 November 2020
  • Emergex Vaccines and George Mason University Identify T-Cell Epitopes Presented by SARS-Cov-2 Infected Cells 15 September 2020

© EMERGEX VACCINES

Website maintained by Digital Trading

  • Contact Us
LinkedIn
Scroll to top